| scholarly article | Q13442814 |
| P50 | author | Marie Davidian | Q42138537 |
| Anastasios Tsiatis | Q44796457 | ||
| P2093 | author name string | J Yin | |
| A S Ruppert | |||
| J C Byrd | |||
| J A Woyach | |||
| S J Mandrekar | |||
| P2860 | cites work | Salvage therapy for CLL and the role of stem cell transplantation | Q46817167 |
| Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens | Q46923051 | ||
| Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience | Q50044415 | ||
| Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. | Q52644817 | ||
| Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | Q64120393 | ||
| Two-stage randomization designs in drug development | Q81499185 | ||
| Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q84932151 | ||
| Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial | Q90315525 | ||
| Treatment of patients with substance use disorders, second edition. American Psychiatic Association | Q95814775 | ||
| Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 | ||
| Reinforcement learning design for cancer clinical trials | Q24648505 | ||
| Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study | Q24658339 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Experimental design and primary data analysis methods for comparing adaptive interventions | Q30571530 | ||
| A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patien | Q33501129 | ||
| Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group | Q33876841 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials | Q34117988 | ||
| An experimental design for the development of adaptive treatment strategies | Q34374570 | ||
| Dynamic treatment regimes: practical design considerations | Q34466674 | ||
| Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
| Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. | Q34722375 | ||
| SMART designs in cancer research: Past, present, and future | Q35607162 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer | Q36206859 | ||
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 | ||
| Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy | Q37434825 | ||
| Phase II design: history and evolution | Q38405280 | ||
| Beyond efficacy: the STAR*D trial | Q43253972 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
| Randomized Clinical Trials | Q60716104 | ||
| P304 | page(s) | 542-550 | |
| P577 | publication date | 2019-04-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia | |
| P478 | volume | 30 |
Search more.